Skip to main content
. 2022 Oct 25;57(1):117–126. doi: 10.1111/apt.17248

FIGURE 1.

FIGURE 1

Corticosteroid‐free clinical remission rates, biochemical remission rates and combined remission rates in all patients (A) and patients treated with at least two different classes of biologicals therapies (e.g. not two anti‐TNF therapies) before initiating tofacitinib (B).